Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting Journal Article

Authors: Luo, J.; Attard, G.; Balk, S. P.; Bevan, C.; Burnstein, K.; Cato, L.; Cherkasov, A.; De Bono, J. S.; Dong, Y.; Gao, A. C.; Gleave, M.; Heemers, H.; Kanayama, M.; Kittler, R.; Lang, J. M.; Lee, R. J.; Logothetis, C. J.; Matusik, R.; Plymate, S.; Sawyers, C. L.; Selth, L. A.; Soule, H.; Tilley, W.; Weigel, N. L.; Zoubeidi, A.; Dehm, S. M.; Raj, G. V.
Article Title: Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Abstract: Context: Although a number of studies have demonstrated the importance of constitutively active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about the precise role of AR-Vs in the progression of castration-resistant prostate cancer (CRPC). Objective: Key stakeholders and opinion leaders in prostate cancer convened on May 11, 2017 in Boston to establish the current state of the field of AR-Vs. Evidence acquisition: The meeting “Mission Androgen Receptor Variants” was the second of its kind sponsored by the Prostate Cancer Foundation (PCF). This invitation-only event was attended by international leaders in the field and representatives from sponsoring organizations (PCF and industry sponsors). Eighteen faculty members gave short presentations, which were followed by in-depth discussions. Discussions focused on three thematic topics: (1) potential of AR-Vs as biomarkers of therapeutic resistance; (2) role of AR-Vs as functionally active CRPC progression drivers; and (3) utility of AR-Vs as therapeutic targets in CRPC. Evidence synthesis: The three meeting organizers synthesized this meeting report, which is intended to summarize major data discussed at the meeting and identify key questions as well as strategies for addressing these questions. There was a critical consensus that further study of the AR-Vs is an important research focus in CRPC. Contrasting views and emphasis, each supported by data, were presented at the meeting, discussed among the participants, and synthesized in this report. Conclusions: This article highlights the state of knowledge and outlines the most pressing questions that need to be addressed to advance the AR-V field. Patient summary: Although further investigation is needed to delineate the role of androgen receptor (AR) variants in metastatic castration-resistant prostate cancer, advances in measurement science have enabled development of blood-based tests for treatment selection. Detection of AR variants (eg, AR-V7) identified a patient population with poor outcomes to existing AR-targeting therapies, highlighting the need for novel therapeutic agents currently under development. Precision detection methods for androgen receptor variants have been developed and will enable treatment selection in men with castration-resistant prostate cancer. Further investigation is needed, and there is a pressing need to develop novel therapeutic approaches to overcome this putative resistance mechanism. © 2017 European Association of Urology
Keywords: abiraterone; castration-resistant prostate cancer; enzalutamide; androgen receptor variant 7; androgen receptor variants
Journal Title: European Urology
Volume: 73
Issue: 5
ISSN: 0302-2838
Publisher: Elsevier Science, Inc.  
Date Published: 2018-05-01
Start Page: 715
End Page: 723
Language: English
DOI: 10.1016/j.eururo.2017.11.038
PROVIDER: scopus
PMCID: PMC5929166
PUBMED: 29258679
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Charles L Sawyers
    150 Sawyers